Skip to main content

Bleeding Disorder

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
XIENCEN/A1 trial
XIENCEN/A1 trial
Active Trials
NCT03355742Completed963Est. Apr 2020
NCT03815175Completed1,605Est. Feb 2021
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
BT524PHASE_31 trial
Active Trials
NCT03444324Completed222Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biotest PharmaceuticalsBT524
AbbottXIENCE
AbbottXIENCE

Clinical Trials (3)

Total enrollment: 2,790 patients across 3 trials

NCT03444324Biotest PharmaceuticalsBT524

Adjusted Fibrinogen Replacement Strategy

Start: Apr 2018Est. completion: Nov 2023222 patients
Phase 3Completed
NCT03815175AbbottXIENCE

XIENCE 28 USA Study

Start: Feb 2019Est. completion: Feb 20211,605 patients
N/ACompleted
NCT03355742AbbottXIENCE

XIENCE 28 Global Study

Start: Feb 2018Est. completion: Apr 2020963 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.